Sarepta Therapeutics (SRPT) News Today $16.80 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$16.89 +0.09 (+0.51%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SRPT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period KROS Stock Guide to Rinvatercept in DMD and ALS for 2026May 22 at 2:06 PM | finance.yahoo.comShould You Buy KROS After Q1 Miss and Takeda Deal Reset?May 22 at 2:06 PM | finance.yahoo.comKROS Turns to Next Wave of TGF-Beta Muscle TherapiesMay 22 at 2:06 PM | finance.yahoo.comWhy Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20, 2026 | finance.yahoo.comImmunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutMay 19, 2026 | proactiveinvestors.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT) and GoodRx Holdings (GDRX)May 17, 2026 | theglobeandmail.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by BrokeragesMay 16, 2026 | americanbankingnews.comSarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target UnchangedMay 15, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Sarepta Therapeutics (SRPT) and Surgery Partners (SGRY)May 14, 2026 | theglobeandmail.comSarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Built On Soft FoundationsMay 14, 2026 | finance.yahoo.comSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | finance.yahoo.comSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | businesswire.comSarepta Therapeutics (SRPT) Gets a Buy from OppenheimerMay 12, 2026 | theglobeandmail.comWells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)May 11, 2026 | theglobeandmail.comA Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline ProgressMay 9, 2026 | finance.yahoo.comVanguard Group Inc. Grows Stock Holdings in Sarepta Therapeutics, Inc. $SRPTMay 9, 2026 | marketbeat.comSarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush SaysMay 8, 2026 | finance.yahoo.comSarepta (SRPT) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comSRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growthMay 8, 2026 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 11.8% - Should You Sell?May 7, 2026 | marketbeat.comSarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.May 7, 2026 | finance.yahoo.comSarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?May 7, 2026 | finance.yahoo.comSarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price TargetMay 7, 2026 | tipranks.comSarepta Therapeutics Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comSarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate DevelopmentsMay 6, 2026 | finance.yahoo.comSarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top EstimatesMay 6, 2026 | finance.yahoo.comSarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to SayMay 6, 2026 | finance.yahoo.comSarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check.May 6, 2026 | finance.yahoo.comSarepta Therapeutics, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 6, 2026 | seekingalpha.comSarepta Therapeutics (NASDAQ:SRPT) Releases Quarterly Earnings ResultsMay 6, 2026 | marketbeat.comSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate DevelopmentsMay 6, 2026 | businesswire.comSarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings GrowthApril 29, 2026 | finance.yahoo.comM&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPTApril 29, 2026 | marketbeat.comSarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comA Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price VolatilityApril 22, 2026 | finance.yahoo.comOcugen Stock Outlook: Valuation, Cash Runway and Dilution RiskApril 22, 2026 | finance.yahoo.comSarepta Therapeutics to Announce First Quarter 2026 Financial ResultsApril 22, 2026 | finance.yahoo.comKROS Rinvatercept: What to Know Before DMD Phase II StartsApril 20, 2026 | finance.yahoo.comKROS 2026 Watchlist: 3 Catalysts That Could Reset SentimentApril 20, 2026 | finance.yahoo.comSarepta Therapeutics Seen Benefiting From New Elevidys Study, Better US Uptake in Second Half of 2026April 17, 2026 | finance.yahoo.comEvercore ISI Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)April 15, 2026 | theglobeandmail.comSarepta Therapeutics (SRPT) price target decreased by 10.97% to 22.48April 15, 2026 | msn.comSarepta Therapeutics (SRPT) price target decreased by 16.58% to 25.25April 9, 2026 | msn.comSarepta siRNA Data Adds New Pillar To Rare Disease Pipeline NarrativeApril 8, 2026 | finance.yahoo.comHow The Sarepta Therapeutics (SRPT) Investment Story Is Shifting On Mixed Elevidys And Pipeline ViewsApril 7, 2026 | finance.yahoo.comWells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)April 2, 2026 | theglobeandmail.com5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats UpApril 1, 2026 | 247wallst.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 31, 2026 | finance.yahoo.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 31, 2026 | businesswire.com Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼0.100.45▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼512▲SRPT Articles Average Week Get the Latest News and Ratings for SRPT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CytomX Therapeutics News Today Editas Medicine News Today Qiagen News Today Kymera Therapeutics News Today Protagonist Therapeutics News Today Spyre Therapeutics News Today Mirum Pharmaceuticals News Today Rhythm Pharmaceuticals News Today Lantheus News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
